OMEROS
Omeros is a Seattle-based commercial-stage biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system.
OMEROS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
1994-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.omeros.com
Total Employee:
51+
Status:
Active
Contact:
2066765005
Total Funding:
965.36 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome Apache
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Euthymics Bioscience
Euthymics Bioscience, a neuroscience-focused biopharmaceutical company, develops medicines for central nervous system disorders.
NovaBay Pharmaceuticals
NovaBay Pharmaceuticals is a biopharmaceutical company developing products for the eye care market.
Oculis
Oculis is a clinical-stage, privately held, pharmaceutical development company focusing on ophthalmic drugs and novel drug delivery.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2006-09-07 | Nura | Nura acquired by Omeros | N/A |
Investors List
CRG
CRG investment in Post-IPO Debt - Omeros
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Omeros
East West Bank
East West Bank investment in Post-IPO Debt - Omeros
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Omeros
East West Bank
East West Bank investment in Post-IPO Debt - Omeros
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Omeros
MidCap Financial
MidCap Financial investment in Post-IPO Debt - Omeros
National Institute of Mental Health
National Institute of Mental Health investment in Grant - Omeros
National Institute on Drug Abuse (NIDA)
National Institute on Drug Abuse (NIDA) investment in Grant - Omeros
Life Sciences Discovery Fund
Life Sciences Discovery Fund investment in Grant - Omeros
Newest Events participated
Official Site Inspections
http://www.omeros.com Semrush global rank: 2.18 M Semrush visits lastest month: 9.05 K
- Host name: 172.67.9.106
- IP address: 172.67.9.106
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Omeros"
Omeros Leadership Team & Board of Directors
Omeros’ leadership team and board of directors contribute diverse expertise and proven leadership, helping us navigate the complex terrain of biopharmaceutical development. ... Dr …See details»
About Omeros – Clinical Studies & Company Milestones
Omeros enters funding agreements for our GPCR discovery program with Vulcan Inc. and Washington State Life Science Discovery Fund . Omeros establishes a charitable entity to fund nonprofit life sciences organizations in Washington …See details»
Omeros - Crunchbase Company Profile & Funding
Omeros is a Seattle-based commercial-stage biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for …See details»
Board of Directors - Omeros
Mr. Cable has served on our board of directors since January 1995 and as our lead independent director since 2010. Mr. Cable is the vice chairman of the board of the Washington Research …See details»
Omeros Corporation - LinkedIn
Omeros Corporation | 10,029 followers on LinkedIn. Let science lead the way | Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small ...See details»
Omeros Corporation Company Profile - Dun & Bradstreet
Company Description: Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for …See details»
Working At Omeros: Company Overview and Culture - Zippia
Mar 14, 2024 Omeros is a Seattle-based commercial-stage biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein …See details»
Omeros Investor Relations - Reports, Filings, OMER Stock Quote
SEATTLE --(BUSINESS WIRE)--Nov. 11, 2024-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September …See details»
Omeros Corporation (OMER) Company Profile & Facts - Yahoo …
See the company profile for Omeros Corporation (OMER) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Annual Reports - Omeros Corporation (OMER)
The Investor Relations website contains information about Omeros Corporation's business for stockholders, potential investors, and financial analysts.See details»
Omeros Corporation Company Information - Drugs.com
Jun 2, 2014 Omeros Corporation Announces FDA Approval of Omidria for Use in Pediatric Patients 12 December 2017; FDA Approves Omidria for Use in Cataract and Other Intraocular …See details»
Omeros Careers
If you have questions about whether a communication purported to be from Omeros is legitimate, please contact us at (206) 676-5000 or [email protected]. Follow Omeros Careers. Hear From …See details»
Omeros Corporation (OMER) Stock Price, Quote & News - Stock …
1 day ago Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan …See details»
Omeros News & Press Releases - Omeros Corporation
Feb 26, 2019 SEATTLE --(BUSINESS WIRE)--Feb. 20, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that, as the company prepares for planned commercialization of …See details»
Omeros Patient Resources: Clinical Trials, Partnerships, & Advocacy
Apr 8, 2019 In everything that we do at Omeros, our primary focus is the patient. Rather than developing “me-too” products, we are tackling serious diseases and disorders to improve or …See details»
Omeros Corporation - Omeros Corporation Reports Fourth …
Dec 23, 2021 – Conference Call Today at 4:30 p.m. ET –. SEATTLE--(BUSINESS WIRE)--Mar. 1, 2022-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company …See details»
Omeros Corporation Further Strengthens its Balance Sheet …
Omeros used the proceeds of the initial term loan and $21.2 million of cash on hand, subject to certain post-closing adjustments, to repurchase $118.1 million aggregate principal amount of …See details»
Omeros Corporation - Omeros Corporation Announces Upcoming ...
SEATTLE--(BUSINESS WIRE)--Dec. 2, 2024-- Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to zaltenibart (OMS906), Omeros’ investigational …See details»
GPCR-Targeted Drugs & Antibody Engineering – Omeros …
Omeros developed a proprietary cellular redistribution assay (CRA) that enables high-throughput identification of synthetic ligands, including antagonists, agonists and inverse agonists, that …See details»